Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU
Crossref DOI link: https://doi.org/10.1007/s40267-017-0413-y
Published Online: 2017-06-02
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McKeage, Kate
Lyseng-Williamson, Katherine A.
License valid from 2017-06-02